MX2021006951A - Formas cristalinas y formas de sal de un inhibidor de cinasa. - Google Patents

Formas cristalinas y formas de sal de un inhibidor de cinasa.

Info

Publication number
MX2021006951A
MX2021006951A MX2021006951A MX2021006951A MX2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A MX 2021006951 A MX2021006951 A MX 2021006951A
Authority
MX
Mexico
Prior art keywords
forms
relates
kinase inhibitor
crystalline forms
compound
Prior art date
Application number
MX2021006951A
Other languages
English (en)
Inventor
Peter Wong
Stephan D Parent
Melanie Janelle Bevill
Khalid Shah
Frenel Demorin
Sagar Shakya
Courtney S Johnson
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2021006951A publication Critical patent/MX2021006951A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formas cristalinas de la base libre del inhibidor de c-Met, Compuesto 1. La invención también se refiere a formas cristalinas de sales del Compuesto 1. La invención también se refiere a composiciones farmacéuticas que comprenden los polimorfos sólidos de la base libre y sales del Compuesto 1. La invención se refiere además a métodos para tratar una enfermedad, trastorno o síndrome mediado al menos en parte por la modulación de la actividad in vivo de una proteína cinasa.
MX2021006951A 2018-12-13 2019-12-12 Formas cristalinas y formas de sal de un inhibidor de cinasa. MX2021006951A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US201962856469P 2019-06-03 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2021006951A true MX2021006951A (es) 2021-07-15

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006951A MX2021006951A (es) 2018-12-13 2019-12-12 Formas cristalinas y formas de sal de un inhibidor de cinasa.

Country Status (20)

Country Link
US (2) US12017995B2 (es)
EP (1) EP3894012A1 (es)
JP (2) JP7509779B2 (es)
KR (1) KR20210102381A (es)
CN (1) CN113329790A (es)
AU (1) AU2019395419A1 (es)
BR (1) BR112021011333A2 (es)
CA (1) CA3122840A1 (es)
CL (1) CL2021001537A1 (es)
CO (1) CO2021007613A2 (es)
CR (1) CR20210375A (es)
GE (1) GEP20247596B (es)
IL (1) IL283860A (es)
MA (1) MA54458A (es)
MX (1) MX2021006951A (es)
PE (1) PE20211757A1 (es)
PH (1) PH12021551356A1 (es)
SG (1) SG11202105949RA (es)
TW (1) TWI852963B (es)
WO (1) WO2020123800A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007765A (es) * 2018-01-26 2020-09-25 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
MA56001A (fr) * 2019-06-03 2022-04-06 Exelixis Inc Formes de sel cristallin d'un inhibiteur de kinase
CN115461328A (zh) * 2020-04-30 2022-12-09 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
MX2023001298A (es) 2020-07-31 2023-02-22 Exelixis Inc Combinaciones para el tratamiento de cancer.
PE20240223A1 (es) 2020-11-05 2024-02-16 Exelixis Inc Composiciones farmaceuticas de un inhibidor de cinasa
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
CN118647603A (zh) 2021-12-22 2024-09-13 埃克塞里艾克西斯公司 激酶抑制剂的结晶形式和盐形式

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
EA026425B1 (ru) 2009-01-16 2017-04-28 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
MX370848B (es) 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
EP3770176A1 (en) 2013-05-02 2021-01-27 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
MX2016010266A (es) 2014-02-14 2017-02-08 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
MX2020007765A (es) * 2018-01-26 2020-09-25 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
MA56001A (fr) * 2019-06-03 2022-04-06 Exelixis Inc Formes de sel cristallin d'un inhibiteur de kinase

Also Published As

Publication number Publication date
CN113329790A (zh) 2021-08-31
US12017995B2 (en) 2024-06-25
CR20210375A (es) 2021-08-18
JP2022512399A (ja) 2022-02-03
BR112021011333A2 (pt) 2021-08-31
PH12021551356A1 (en) 2021-12-06
US20240300897A1 (en) 2024-09-12
US20230029213A1 (en) 2023-01-26
GEP20247596B (en) 2024-02-26
JP7509779B2 (ja) 2024-07-02
JP2024038167A (ja) 2024-03-19
MA54458A (fr) 2021-10-20
AU2019395419A1 (en) 2021-07-01
TWI852963B (zh) 2024-08-21
CO2021007613A2 (es) 2021-06-21
KR20210102381A (ko) 2021-08-19
WO2020123800A1 (en) 2020-06-18
IL283860A (en) 2021-07-29
EP3894012A1 (en) 2021-10-20
CL2021001537A1 (es) 2022-02-04
CA3122840A1 (en) 2020-06-18
SG11202105949RA (en) 2021-07-29
TW202039440A (zh) 2020-11-01
PE20211757A1 (es) 2021-09-07

Similar Documents

Publication Publication Date Title
MX2021006951A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa.
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
PH12020552187A1 (en) Pcsk9 antagonist compounds
EA201690752A1 (ru) Ингибиторы g12c kras
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.
EA201991884A3 (ru) Ингибиторы g12c kras
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2023010303A (es) Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
MX2021012105A (es) Compuestos de pirrol.
PH12019502868A1 (en) Composition for injection
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
PH12019501566A1 (en) Amide compounds and use thereof
MX2023005273A (es) Composiciones farmaceuticas de un inhibidor de cinasa.
CY1123185T1 (el) Παραγωγα ινδολιου
EA202190452A1 (ru) Ингибиторы cdk8/19
EA202191653A1 (ru) Кристаллические формы и солевые формы ингибитора киназы
MX2024009648A (es) Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida.
MY198328A (en) Adamantylmethylamine Derivative and use Thereof as Pharmaceutical